266 related articles for article (PubMed ID: 27755245)
21. Analysis of redox and apoptotic effects of anthracyclines to delineate a cardioprotective strategy.
Fulbright JM; Egas-Bejar DE; Huh WW; Chandra J
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1297-307. PubMed ID: 26515054
[TBL] [Abstract][Full Text] [Related]
22. New iron chelators in anthracycline-induced cardiotoxicity.
Kaiserová H; Simunek T; Sterba M; den Hartog GJ; Schröterová L; Popelová O; Gersl V; Kvasnicková E; Bast A
Cardiovasc Toxicol; 2007; 7(2):145-50. PubMed ID: 17652820
[TBL] [Abstract][Full Text] [Related]
23. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron.
Simůnek T; Stérba M; Popelová O; Adamcová M; Hrdina R; Gersl V
Pharmacol Rep; 2009; 61(1):154-71. PubMed ID: 19307704
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic Changes Associated With Anthracycline-Induced Cardiotoxicity.
Tantawy M; Pamittan FG; Singh S; Gong Y
Clin Transl Sci; 2021 Jan; 14(1):36-46. PubMed ID: 32770710
[TBL] [Abstract][Full Text] [Related]
25. Current views on anthracycline cardiotoxicity.
Mele D; Nardozza M; Spallarossa P; Frassoldati A; Tocchetti CG; Cadeddu C; Madonna R; Malagù M; Ferrari R; Mercuro G
Heart Fail Rev; 2016 Sep; 21(5):621-34. PubMed ID: 27230651
[TBL] [Abstract][Full Text] [Related]
26. Cardioprotection in cancer therapy: novel insights with anthracyclines.
Raber I; Asnani A
Cardiovasc Res; 2019 Apr; 115(5):915-921. PubMed ID: 30726931
[TBL] [Abstract][Full Text] [Related]
27. Chemotherapy-induced cardiotoxicity: new insights into mechanisms, monitoring, and prevention.
Cadeddu Dessalvi C; Deidda M; Mele D; Bassareo PP; Esposito R; Santoro C; Lembo M; Galderisi M; Mercuro G
J Cardiovasc Med (Hagerstown); 2018 Jul; 19(7):315-323. PubMed ID: 29708912
[TBL] [Abstract][Full Text] [Related]
28. Long-term and short-term models for studying anthracycline cardiotoxicity and protectors.
Robert J
Cardiovasc Toxicol; 2007; 7(2):135-9. PubMed ID: 17652818
[TBL] [Abstract][Full Text] [Related]
29. Anthracycline cardiotoxicity.
Menna P; Paz OG; Chello M; Covino E; Salvatorelli E; Minotti G
Expert Opin Drug Saf; 2012 May; 11 Suppl 1():S21-36. PubMed ID: 21635149
[TBL] [Abstract][Full Text] [Related]
30. Anthracycline-related cardiotoxicity in childhood cancer survivors.
Lipshultz SE; Karnik R; Sambatakos P; Franco VI; Ross SW; Miller TL
Curr Opin Cardiol; 2014 Jan; 29(1):103-12. PubMed ID: 24284979
[TBL] [Abstract][Full Text] [Related]
31. Metallothionein as a Scavenger of Free Radicals - New Cardioprotective Therapeutic Agent or Initiator of Tumor Chemoresistance?
Heger Z; Rodrigo MA; Krizkova S; Ruttkay-Nedecky B; Zalewska M; Del Pozo EM; Pelfrene A; Pourrut B; Stiborova M; Eckschlager T; Emri G; Kizek R; Adam V
Curr Drug Targets; 2016; 17(12):1438-51. PubMed ID: 26424389
[TBL] [Abstract][Full Text] [Related]
32. Anthracyclines/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms.
Rochette L; Guenancia C; Gudjoncik A; Hachet O; Zeller M; Cottin Y; Vergely C
Trends Pharmacol Sci; 2015 Jun; 36(6):326-48. PubMed ID: 25895646
[TBL] [Abstract][Full Text] [Related]
33. The genetic underpinnings of anthracycline-induced cardiomyopathy predisposition.
Berkman AM; Hildebrandt MAT; Landstrom AP
Clin Genet; 2021 Aug; 100(2):132-143. PubMed ID: 33871046
[TBL] [Abstract][Full Text] [Related]
34. Coenzyme q10 for prevention of anthracycline-induced cardiotoxicity.
Conklin KA
Integr Cancer Ther; 2005 Jun; 4(2):110-30. PubMed ID: 15911925
[TBL] [Abstract][Full Text] [Related]
35. Chemotherapy-induced cardiomyopathy.
Higgins AY; O'Halloran TD; Chang JD
Heart Fail Rev; 2015 Nov; 20(6):721-30. PubMed ID: 26338137
[TBL] [Abstract][Full Text] [Related]
36. Anthracycline-Induced Cardiotoxicity in Young Cancer Patients: The Role of Carnitine.
Armenian SH
Ann Nutr Metab; 2016; 68 Suppl 3():10-14. PubMed ID: 27931027
[TBL] [Abstract][Full Text] [Related]
37. Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens.
Cadeddu Dessalvi C; Pepe A; Penna C; Gimelli A; Madonna R; Mele D; Monte I; Novo G; Nugara C; Zito C; Moslehi JJ; de Boer RA; Lyon AR; Tocchetti CG; Mercuro G
Heart Fail Rev; 2019 Nov; 24(6):915-925. PubMed ID: 31256318
[TBL] [Abstract][Full Text] [Related]
38. Cardiotoxicity of anticancer treatments: what the cardiologist needs to know.
Ewer MS; Ewer SM
Nat Rev Cardiol; 2010 Oct; 7(10):564-75. PubMed ID: 20842180
[TBL] [Abstract][Full Text] [Related]
39. Chronic heart damage following doxorubicin treatment is alleviated by lovastatin.
Henninger C; Huelsenbeck S; Wenzel P; Brand M; Huelsenbeck J; Schad A; Fritz G
Pharmacol Res; 2015 Jan; 91():47-56. PubMed ID: 25462173
[TBL] [Abstract][Full Text] [Related]
40. Role of anthracyclines in the era of targeted therapy.
Cortés-Funes H; Coronado C
Cardiovasc Toxicol; 2007; 7(2):56-60. PubMed ID: 17652804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
